Avrobio halts gene therapy research and considers a sale
Bio Pharma Dive
JULY 12, 2023
The decision to explore “strategic alternatives” comes about six weeks after the company sold its most advanced treatment to Novartis for nearly $90 million.
Pfizer to deepen cost cuts as latest sales forecasts miss expectations
Bio Pharma Dive
DECEMBER 13, 2023
The company is now expecting to save $4 billion by the end of 2024, with a majority of the spending cuts coming from drug research and development.
Sales 
286
286 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Gene editing biotech Homology hits reset and seeks a sale
Bio Pharma Dive
JULY 28, 2023
The company will lay off 87% of its workforce and halt further research, including for a gene editing therapy to treat the rare disease PKU.
Gene Editing 246
246 
DoP to frame ‘Disposal Policy’ for safe removal of unused and expired drugs from household & sale premises
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 10, 2024
In order to avoid environmental hazards due to pharmaceutical products, the Department of Pharmaceuticals (DoP) is thinking of framing a ‘Disposal Policy’ for removing the unused and date-expired drugs from the sale premises and from the households.
Sales 188
188 
Medical devices industry asks govt to define and bring clarity on online sale of devices in New Drugs Bill, 2022
AuroBlog - Aurous Healthcare Clinical Trials blog
SEPTEMBER 14, 2022
The medical devices industry in the country has sought the Centre to define online and offline mode of sale, provide more clarity on the regulations that are binding the online sales and suggested inclusion of online medical devices players under the Uniform Code for Medical Devices Marketing Practices (UCMDMP).
Sales 182
182 
Artificial Intelligence (AI) in Pharma Sales and Marketing
Pharma Mirror
OCTOBER 17, 2022
AI research has been defined as the field of study of intelligent agents, which refers to any system that perceives its environment and takes actions that maximize its chance of achieving its goals. The post Artificial Intelligence (AI) in Pharma Sales and Marketing appeared first on Pharma Mirror Magazine. What is AI?
Sales 130
130 
Novavax cuts workforce by 25% as COVID vaccine sales fall
Bio Pharma Dive
MAY 9, 2023
The layoffs, which will affect hundreds of employees, are part of a major restructuring designed to reduce operational and research spending by as much as half.
Sales 177
177 
Top biopharmaceutical Covid-19 vaccine companies boosted with over 80% revenue growth
Pharmaceutical Technology
SEPTEMBER 15, 2022
As a result of huge global sales of mRNA Covid-19 vaccines, the split in profits between Pfizer and BioNTech’s Comirnaty contributed towards revenues of $81.3bn and $22.4bn last year, respectively. Pfizer reaped $36.8bn from Comirnaty, the highest revenue generated from Covid-19 vaccine sales worldwide. YoY revenue growth.
Vaccination 272
272 
Aurinia to cut research after sale process fails to find a buyer
Bio Pharma Dive
FEBRUARY 15, 2024
The Canadian lupus drug developer said it engaged more than 60 parties during its eight-month business review, but only one expressed interest before walking away.
Sales 136
136 
Pharma is “big business” that uses excuses to keep prices high
World of DTC Marketing
OCTOBER 5, 2021
last year gave away more than $23 billion in rebates to insurance intermediaries, but still netted $50 billion in sales. sales of the 20 top-selling drugs worldwide totaled $101.1 billion while sales to the rest of the world totaled nearly $57 billion. Drugs with significant sales revenue disparities between the U.S.
Sales 241
241 
Ono Pharmaceutical enters research deal with Monash University
Pharmaceutical Technology
JANUARY 16, 2023
Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs). Monash University will receive an upfront payment from Ono Pharmaceutical in addition to research funding that will be provided during the option period.
Research 130
130 
DTAB recommends prohibiting pain relief combination S(+) etodolac+paracetamol
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 11, 2024
The Drugs Technical Advisory Board (DTAB) of the Union health ministry has once again recommended prohibiting the manufacture, sale and distribution of pain relief drug combination S(+) etodolac+paracetamol, after considering a sub-committee report.
Manufacturing 246
246 
Blockchain: Ready to revolutionise medicinal cannabis research?
pharmaphorum
JUNE 29, 2021
As cannabis legalisation spreads, so too does medical research into all the benefits we can derive from THC, CBD, and the various terpenes to be found in the cannabis flower. Thus a blockchain can track anything from the sale and ownership of a few dogecoins to the entire life cycle of a sensitive clinical trial.
Medicine 130
130 
Ginkgo and Boehringer partner to develop hard-to-treat disease therapies
Pharmaceutical Technology
MAY 9, 2023
Ginkgo will receive an initial research payment and an aggregate total of $406m in success-based research and development payments, regulatory and commercial milestones and royalties on sales.
Development 261
261 
Biden proposes subsidizing drug middlemen for insulin
World of DTC Marketing
MARCH 31, 2022
Research shows that the three-drug companies that dominate global insulin sales — Novo Nordisk, Eli Lilly, and Sanofi may not be entirely to blame for the soaring costs to people with diabetes. In 2014, researchers determined, 30% of insulin revenue went to middlemen. Los Angeles Times.
Insulin 240
240 
Pharma sector reels as UK Government doubles VPAS payback rate on NHS drugs
Pharmaceutical Technology
JANUARY 30, 2023
on National Health Service (NHS) sales of branded medicines in 2023, almost double that of the previous year, has sent shock waves through the pharma industry. During 2019–21, when sales being close to predicted levels resulted in single-digit payback rates, the scheme was relatively popular with the pharma sector. billion ($4.1
Sales 243
243 
7 commercial, sales, and marketing predictions for 2023
pharmaphorum
DECEMBER 23, 2022
Rarely are organisations able to view HCP relationships holistically – across clinical, medical, and sales – or reap the benefits of creating a unified understanding of the customer. In 2023, omnichannel behaviours will directly influence incentive compensation models by correlating successful engagement data to successful sales outcomes.
Sales 105
105 
Eli Lilly’s Tirzepatide Shows Promise for Keeping Prediabetic Patients Diabetes-Free
XTalks
NOVEMBER 21, 2024
Researchers monitored a range of health metrics, including fasting glucose, HbA1c levels and weight changes. While GlobalData predicts that Mounjaro and Zepbound will contribute to GLP-1 drugs becoming the best-selling drug class this year, sales of the drugs have been slightly lower than anticipated. billion, below the anticipated $1.7
Sales 105
105 
Cyagen and Neurophth partner to develop gene therapy vectors
Pharmaceutical Technology
NOVEMBER 8, 2022
Under the collaboration, Cyagen is entitled to get research phase and clinical phase milestone payments and sales-based royalty payments totalling over $140m. Additionally, Neurophth will oversee the clinical trials and marketing of gene therapy products developed leveraging the new AAV capsids of Cyagen.
Gene Therapy 305
305 
Top 3 Best-Selling Eye Drugs by Recent Sales Data
XTalks
JANUARY 3, 2025
In this blog, we delve into the recent sales data to highlight the top three best-selling eye drugs in 2023. Lets take a closer look at Eylea, Vabysmo and Lucentis the ophthalmology drugs that led the pack in recent sales figures. Related: Top 30 Drugs to Watch in 2024: Insights from 2023 Sales Data 1. billion, down from $1.50
Sales 85
85 
New Anti-Hangover Pill Claims to Rapidly Break Down Alcohol, But Does It Work?
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 10, 2022
A new anti-hangover supplement has just gone on sale in the UK. It is marketed by Swedish firm Myrkl as “the pre-drinking pill that works” The pill is said to break down up to 70 percent of alcohol after 60 minutes. This means that if someone drinks 50 ml of 40 percent spirits, which contains […].
Containment 246
246 
Alligator Bioscience and Orion expand immuno-oncology research alliance
Pharmaceutical Technology
JANUARY 3, 2023
Alligator Bioscience and Orion are initiating the second programme of their immuno-oncology research collaboration and licence agreement. Alligator is entitled to receive milestone payments of up to $500.78m (€469m) for the development, approval, and sales of the three potential programmes.
Research 130
130 
Twist Bioscience and Astellas team up for antibody discovery
Pharmaceutical Technology
APRIL 21, 2023
In May 2022, they signed a research partnership and exclusive option licence agreement for the development of antibodies to reduce tumour microenvironment-mediated immunosuppression. The companies signed another research collaboration agreement for multi-target antibody discovery in January 2023.
Antibody 264
264 
Centre puts onus on SLAs to take action against e-pharmacies for violation of D&C Act and Rules
AuroBlog - Aurous Healthcare Clinical Trials blog
MARCH 23, 2023
With the chemists and druggists across the country opposing the sale of drugs through online, the Central government is taking a stand that the sale of medicines should be strictly under the provisions of the existing regulations and the State Licensing Authorities (SLAs) are legally empowered to act against violation of the legal provisions.
Pharmacy 188
188 
Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry
Pharma Marketing Network
JULY 19, 2023
Content Marketing as a Sales Driver: Unlocking Your Business Potential in the Pharmaceutical Industry Content marketing is a long-term strategy that can help businesses of all sizes generate leads, increase brand awareness, and drive sales. Driving sales: Ultimately, the goal of content marketing is to drive sales.
Sales 98
98 
Eisai and Washington University to develop neurodegenerative disease therapies
Pharmaceutical Technology
DECEMBER 15, 2022
Eisai has entered a comprehensive research partnership agreement with Washington University School of Medicine in St Louis, US, to develop potential new therapies for neurodegenerative ailments. By collaborating with world-leading research institutions such as Washington University in St.
Development 246
246 
Sanofi and Innate Pharma extend cancer therapeutics partnership
Pharmaceutical Technology
DECEMBER 19, 2022
Innate is also eligible to receive a total of up to $1.43bn (€1.35bn) in preclinical, clinical, regulatory and commercial milestone payments and royalty payments on net sales in the future. Initially, the companies signed a research collaboration and licensing agreement in 2016 to develop and assess up to two bispecific NK cell engagers.
Development 264
264 
Atomwise and Sanofi partner for drug discovery using AI
Pharmaceutical Technology
AUGUST 18, 2022
Atomwise and Sanofi have entered a strategic and exclusive research partnership to use the former’s artificial intelligence (AI)-driven AtomNet platform to discover and research up to five drug targets computationally. These targets will be exclusive to Sanofi.
Drugs 246
246 
Hookipa partners with Roche for cancer immunotherapy development
Pharmaceutical Technology
OCTOBER 21, 2022
Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers. Following the marketing of both programmes, Hookipa will also receive tiered royalty payments on the global net product sales.
Development 278
278 
Quanta raises more than $50 million for KRAS inhibitor research
Pharmaceutical Technology
MAY 23, 2023
Last month, the South San Francisco, California-headquartered company presented preclinical data on its KRAS inhibitor pipeline, which includes QTX3034 and QTX3046 at the Annual Meeting of the American Association for Cancer Research in Orlando, Florida. billion in 2029. GlobalData is the parent company of Pharmaceutical Technology.
Research 130
130 
Astellas and Sutro partner to develop immunostimulatory ADCs
Pharmaceutical Technology
JUNE 28, 2022
The alliance will utilise the cancer-fighting potential of iADCs as a new modality, along with the expertise of Sutro to engineer complex conjugated antibodies and the global oncology research and development (R&D) capabilities of Astellas. Astellas and Sutro will expedite the development of iADCs for three different biological targets.
Development 264
264 
Gilead wins patent battle with US government over HIV PrEP drugs
Pharmaceutical Technology
MAY 10, 2023
According to the US government, Gilead had repeatedly refused to license patents related to PrEP research undertaken by the Department of Health and Human Services’ (HHS) Centers for Disease Control and Prevention (CDC). This research dates to the mid-2000s when CDC scientists developed the PrEP regimen, argued the government.
Drugs 264
264 
Delhi HC bans Zydus’ biosimilar Sigrima in a landmark injunction order
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 17, 2024
Roche had sought injunctive reliefs against the sale and distribution of Sigrima and Womab, which purportedly infringes […] As per the Delhi HC order, Zydus and Dr Reddy’s launched ‘Sigrima/Womab,’ a biosimilar of Roche’s ‘Perjeta’ (pertuzumab), in a clear contempt of court.
Sales 189
189 
New FDA head needs to examine the accelerated approval program
World of DTC Marketing
OCTOBER 21, 2021
The analysis focused on Medicare Part B and Part D spending — which covers outpatient medical care and prescription drugs, respectively, — in 2017, 2018 and 2019, the researchers said. That money is gone without any clinical benefit and the executives at those drug companies received compensation because of those sales.
Clinical Trials 234
234 
Health ministry issues notification to include antiviral drugs oseltamivir & zanamivir into Schedule H1
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 4, 2023
The Union health ministry has issued a draft notification to include antiviral drugs oseltamivir and zanamivir into the Schedule H1 of the Drug Rules, 1945, allowing the retailers to store and sell the drug against prescription by maintaining a separate record for the details of the particular sales.
Drugs 189
189 
The future of pain medication: are cannabinoids the solution to the opioid epidemic?
Pharmaceutical Technology
JUNE 12, 2023
In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker.
Drugs 358
358 
Health ministry bans use of ketoprofen and aceclofenac for animal use
AuroBlog - Aurous Healthcare Clinical Trials blog
AUGUST 7, 2023
The Union health ministry has issued a notification prohibiting the manufacture, sale and distribution of pain killers, ketoprofen and aceclofenac and their formulations for animal use with immediate effect, as they are likely to involve risk to animals.
Sales 187
187 
Delhi HC grants 10 days’ time to Govt to file counter affidavit on petitions against ban of 14 FDCs
AuroBlog - Aurous Healthcare Clinical Trials blog
JULY 11, 2023
The Delhi High Court has granted ten days’ time to the Government of India and the nation’s drug regulator to file a counter affidavit on the petitions filed by almost 28 pharma companies against the order prohibiting manufacturing, distribution and sale of 14 FDCs licensed prior to the year 1988, in the beginning of June. […]
Pharma Companies 186
186 
Pharma’s move to digital Part 1 HCP Marketing
World of DTC Marketing
JANUARY 18, 2021
Before COVID-19, 64% of meetings with pharma sales reps were held in person. HCPs said they still want to learn about new treatments and interact with pharma sales reps – they just want to do so in different ways. And, in fact, 61% said they are interacting with pharma sales reps more during COVID-19 than they did before.
Marketing 173
173 
Beverage & Food IPOs in 2025: Companies Taking the Public Leap
XTalks
MARCH 26, 2025
billion in sales, marking a turnaround from the prior years losses. Moreover, Marwynn will be expanding production and pursuing regulatory certifications in Europe and Asia, backed by ongoing research to enhance ingredient performance, nutritional profiles and global market readiness. billion in revenue.
Packaging 105
105 
uniQure signs license deal for Apic Bio’s gene therapy for SOD1-ALS
Pharmaceutical Technology
JANUARY 31, 2023
uniQure research and development president Ricardo Dolmetsch said: “The licensing of APB-102 provides uniQure with another clinical stage program that is strategically aligned with our current pipeline and highly complementary with our AMT-161 programme for the treatment of ALS caused by mutations in the c9orf72 gene.
Gene Therapy 277
277 
Warnings for Japanese pharmaceutical market may lead to more lenient price controls
Pharmaceutical Technology
NOVEMBER 21, 2022
billion) in total sales in 2021 and is expected to grow 1.1% However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR). in 2022 to JPY9.498 trillion ($68.08
Marketing 173
173 
Omnichannel marketing is the answer but what’s the question?
World of DTC Marketing
NOVEMBER 16, 2021
The medical industry is shifting from a model that revolves around sales reps to an omnichannel world in which HCPs are able to access information as and when they need it. The other issue is that some specialties rely heavily on their relationship with the sales rep.
Marketing 253
253 
Gilead reports 1% rise in revenue for Q2 2022
Pharmaceutical Technology
AUGUST 3, 2022
The company attributed the revenue rise to enhanced sales in HIV and oncology products, which was offset partially by reduced sales of Veklury (remdesivir) and hepatitis C virus (HCV) medicines. Total product sales in the second quarter of 2022 were $6.13bn versus $6.15bn in the prior-year quarter. from $1.21 in Q2 2021.
Sales 130
130 
Let's personalize your content